Carlton Fleming

Carlton’s substantial experience includes the following representative matters:

• Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, in its initial public offering and multiple follow-on equity offerings.
• Cytokinetics, Incorporated, a biotech company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue, in its US$138 million offering of senior notes and multiple follow-on equity offerings.
• DocuSign, Inc., a provider of a leading eSignature solution, in its:
  • US$723.7 million initial public offering;
  • US$443.3 million follow-on equity offering and concurrent offering US$575 million 0.5% convertible senior notes due 2023; and
  • US$188 million acquisition of Seal Software, a leading contract analytics and artificial intelligence technology provider.
• Kodiak Sciences Inc., a clinical stage company engaged in developing innovative therapeutics to treat high prevalence of ophthalmic diseases, in its:
  • US$312 million and US$645 million follow-on equity offerings; and
  • US$225 million royalty financing transaction.
• NGM Biopharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing transformative therapeutics for patients, on its US$106.7 million initial public offering and US$143.8 million follow-on offering.
• Talis Biomedical Corporation, a company developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, in its US$232.5 million initial public offering.
• Twilio Inc., a publicly traded cloud communications platform, in its US$1.8 billion public offering of Class A common stock and US$1.0 billion public offering of senior notes.
• Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines, in its US$287.5 million initial public offering.

*Certain of the matters above were handled prior to joining Sidley